中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | YP115026 |
|---|---|
| 종 반응성 | General |
| 응용 분야 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 숙주 종 | Chimeric |
| 클론성 | Monoclonal |
| 이소타입 | IgG1-kappa |
| 클론 ID | Lorukafusp Alfa |
| 생물학적 활성 | Ganglioside GD2 is associated with tumor development and malignant phenotypes, and its mechanism of action involves enhancing cell proliferation, motility, migration, adhesion and invasion, with specific effects depending on tumor type [1]. |
| 발현 시스템 | Mammalian cells |
| 타겟 | Ganglioside GD2 |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% purity as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | CAS: 65988-71-8 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | 14.18 mAb, 14.18-IL-2, EMD273063, EMD 273063, EMD-273063, Hu14.18-IL-2, Hu14.18-IL2, anti-GD2 fused to IL2, hu14.18-IL2, hu14.18-Interleukin-2 fusion protein, CAS: 2131168-99-3 |
| 배경 | Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity. • Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246 • GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214 • Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230 • Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234 • Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234 • Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849 • RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168 • Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas., PMID:29662203 • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881 |
| 참고 문헌 | 1. Nazha B, et al. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020;10:1000. Published 2020 Jul 7. [YP115026] 2. Erber R, et al. Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers (Basel). 2021;13(21):5577. Published 2021 Nov 8. [YP115026] |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Lorukafusp Alfa
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
